Cue Biopharma, Inc. (FRA:1UC)
Germany · Delayed Price · Currency is EUR 0.5380
+0.0070 (1.32%)
At close: Nov 28, 2025
Cue Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 7.1 | 9.29 | 5.49 | 1.25 | 14.94 | 3.15 | Upgrade | |
Revenue Growth (YoY) | -25.51% | 69.16% | 340.96% | -91.67% | 373.68% | -8.79% | Upgrade |
Cost of Revenue | 35.43 | 36.3 | 40.8 | 35.3 | 41.35 | 33.55 | Upgrade |
Gross Profit | -28.33 | -27.01 | -35.31 | -34.05 | -26.41 | -30.39 | Upgrade |
Selling, General & Admin | 16.51 | 14.59 | 16.68 | 19.45 | 17.31 | 14.65 | Upgrade |
Research & Development | -6.73 | - | - | - | - | - | Upgrade |
Operating Expenses | 9.78 | 14.59 | 16.68 | 19.45 | 17.31 | 14.65 | Upgrade |
Operating Income | -38.11 | -41.59 | -51.99 | -53.5 | -43.71 | -45.04 | Upgrade |
Interest Expense | -0.46 | -0.8 | -1.25 | -0.71 | - | - | Upgrade |
Interest & Investment Income | 0.94 | 1.62 | 2.66 | 0.93 | 0.05 | 0.54 | Upgrade |
EBT Excluding Unusual Items | -37.63 | -40.77 | -50.58 | -53.29 | -43.67 | -44.5 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.08 | Upgrade |
Gain (Loss) on Sale of Assets | -0.06 | 0.09 | -0.16 | 0.28 | - | - | Upgrade |
Pretax Income | -37.68 | -40.67 | -50.73 | -53.01 | -43.67 | -44.58 | Upgrade |
Income Tax Expense | - | - | - | - | 0.5 | 0.21 | Upgrade |
Net Income | -37.68 | -40.67 | -50.73 | -53.01 | -44.16 | -44.78 | Upgrade |
Net Income to Common | -37.68 | -40.67 | -50.73 | -53.01 | -44.16 | -44.78 | Upgrade |
Shares Outstanding (Basic) | 86 | 56 | 46 | 36 | 31 | 29 | Upgrade |
Shares Outstanding (Diluted) | 86 | 56 | 46 | 36 | 31 | 29 | Upgrade |
Shares Change (YoY) | 74.30% | 23.11% | 28.35% | 13.95% | 9.05% | 30.16% | Upgrade |
EPS (Basic) | -0.44 | -0.72 | -1.11 | -1.49 | -1.41 | -1.56 | Upgrade |
EPS (Diluted) | -0.44 | -0.72 | -1.11 | -1.49 | -1.41 | -1.56 | Upgrade |
Free Cash Flow | -29.82 | -36.4 | -39.96 | -41.98 | -39.75 | -33.09 | Upgrade |
Free Cash Flow Per Share | -0.34 | -0.65 | -0.87 | -1.18 | -1.27 | -1.15 | Upgrade |
Gross Margin | - | -290.81% | - | - | -176.73% | - | Upgrade |
Operating Margin | -536.73% | -447.86% | -947.03% | -4297.35% | -292.56% | -1427.96% | Upgrade |
Profit Margin | -530.75% | -437.97% | -924.10% | -4257.83% | -295.56% | -1419.79% | Upgrade |
Free Cash Flow Margin | -419.97% | -391.89% | -727.89% | -3371.65% | -266.04% | -1049.01% | Upgrade |
EBITDA | -37.73 | -41.2 | -51.44 | -52.58 | -42.45 | -43.99 | Upgrade |
EBITDA Margin | - | - | - | - | -284.14% | - | Upgrade |
D&A For EBITDA | 0.38 | 0.4 | 0.56 | 0.92 | 1.26 | 1.06 | Upgrade |
EBIT | -38.11 | -41.59 | -51.99 | -53.5 | -43.71 | -45.04 | Upgrade |
EBIT Margin | - | - | - | - | -292.56% | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.